The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
“European Panel on Low Density Lipoprotein (LDL) Subclasses”: A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses
Open accessAbstract
Aim of the present Consensus Statement is to provide a comprehensive and up to-date document on the pathophysiology, atherogenicity and clinical significance of low density lipoproteins (LDL) subclasses. We sub-divided our Statement in 2 sections: section I discusses the pathophysiology, atherogenicity and measurement issues, while section II is focused on the effects of drugs and lifestlyle modifications. Suggestions for future research in the field are highlighted at the end of section II. Each section includes Conclusions. Keywords: LDL, subclasses, atherosclerosis, cardiovascular risk, statement, hypertriglyceridaemia, coronary heart disease, cardiovascular disease, apolipoprotein, chylomicrons
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
Després, J.-P., Golay, A., & Sjöström, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044537 · Cited by 1,392
Effects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol
Brousseau, M. E., Schaefer, E. J., Wolfe, M. L., Bloedon, L. T., Digenio, A. G., Clark, R. W., Mancuso, J. P., & Rader, D. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031766 · Cited by 774
Drug treatments for obesity: orlistat, sibutramine, and rimonabant
Padwal, R. S., & Majumdar, S. R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60033-6 · Cited by 753
Grundy, S. M. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.14.1568 · Cited by 551
Zambon, A., Hokanson, J. E., Brown, B. G., & Brunzell, J. D. (1999) · Circulation · doi:10.1161/01.cir.99.15.1959 · Cited by 263
Self-citationDreon, D., Fernstrom, H., Campos, H., Blanche, P., Williams, P., & Krauss, R. (1998) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/67.5.828 · Cited by 170
Seshadri, P., Iqbal, N., Stern, L., Williams, M., Chicano, K. L., Daily, D. A., McGrory, J., Gracely, E. J., Rader, D. J., & Samaha, F. F. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.04.009 · Cited by 169
Volek, J. S., Sharman, M. J., Gómez, A. L., DiPasquale, C., Roti, M., Pumerantz, A., & Kraemer, W. J. (2004) · Journal of the American College of Nutrition · doi:10.1080/07315724.2004.10719359 · Cited by 164
Cited by
Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases
Trpkovic, A., Resanovic, I., Stanimirovic, J., Radak, D., Mousa, S. A., Cenic-Milosevic, D., Jevremovic, D., & Isenovic, E. R. (2015) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2014.992063 · Cited by 321
Nikolic, D., Giglio, R. V., Rizvi, A. A., Patti, A. M., Montalto, G., Maranta, F., Cianflone, D., Stoian, A. P., & Rizzo, M. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00962-3 · Cited by 81
Self-citationLanglois, M. R., Descamps, O. S., van der Laarse, A., Weykamp, C., Baum, H., Pulkki, K., von Eckardstein, A., De Bacquer, D., Borén, J., Wiklund, O., et al. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.12.016 · Cited by 72
Ursoniu, S., Sahebkar, A., Serban, M.-C., Antal, D., Mikhailidis, D. P., Cicero, A., Athyros, V., Rizzo, M., Rysz, J., & Banach, M. (2017) · Nutrition Reviews · doi:10.1093/nutrit/nuw063 · Cited by 48
Self-citationMuzurović, E., & Mikhailidis, D. P. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1795132 · Cited by 35
Self-citation
Metadata
- Authors
- P. Mikhailidis, D., Elisaf, M., Rizzo, M., Berneis, K., Griffin, B., Zambon, A., Athyros, V., de Graaf, J., Marz, W., G. Parhofer, K., Battista Rini, G., A. Spinas, G., H. Tomkin, G., D. Tselepis, A., S. Wierzbicki, A., Winkler, K., Florentin, M., & Liberopoulos, E.
- Venue
- Current Vascular Pharmacology
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2011-09-01
- Volume
- 9
- Issue
- 5
- Pages
- 533-571
- ISSN
- 1570-1611 (ISSN-L)
- OpenAlex
- W2106285042
- Cited by
- 198
- References
- 18
- FWCI
- 25.31
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: “European Panel on Low Density Lipoprotein (LDL) Subclasses”: A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses. https://app.cochat.ai/papers/10.2174/157016111796642661
- The paper
- P. Mikhailidis, D., Elisaf, M., Rizzo, M., Berneis, K., Griffin, B., Zambon, A., Athyros, V., de Graaf, J., Marz, W., G. Parhofer, K., Battista Rini, G., A. Spinas, G., H. Tomkin, G., D. Tselepis, A., S. Wierzbicki, A., Winkler, K., Florentin, M., & Liberopoulos, E. (2011). “European Panel on Low Density Lipoprotein (LDL) Subclasses”: A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses. Current Vascular Pharmacology. https://doi.org/10.2174/157016111796642661
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.